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Background
Trafficking of AMPA receptors (AMPARs) underlies the
activity-dependent modification of synaptic strength and
is regulated by specific interactions of AMPAR subunits
with other proteins. We have reported (Serulle et al.,
2007) [1] that the AMPAR subunit GluR1 binds the
cGMP-dependent kinase type II (cGKII) adjacent to the
kinase catalytic site, and that this interaction is increased
by cGMP. In this complex, cGKII phosphorylates GluR1 at
serine 845 (S845) leading to an increase of GluR1 on the
plasma membrane. In neurons, cGMP is produced by sol-
uble guanylate cyclase (sGC), which is activated by nitric
oxide (NO), which is produced by nNOS under the con-
trol of the NMDA receptor.
Results
To distinguish the mechanism, we have measured the rate
of exogenous GluR1 endocytosis in cultured primary neu-
rons, either the wild type or the S845A or S845D mutants
(Figure 1). We find that the S845A mutant (which cannot
be phosphorylated) is endocytosed at rate of the wild
type, while S845D (phosphomimetic) is endocytosed at a
lower rate. Also, cGMP treatment, which elevates the
endogenous GluR1 plasma membrane levels (Figure 2A),
reduced the rate of of GluR1 endocytosis (Figure 2B).
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Endocytosis of HAGluR1 is time dependent and is inhibited by the pho phomimetic mutation, S845DFigure 1
Endocytosis of HAGluR1 is time dependent and is 
inhibited by the phosphomimetic mutation, S845D.Page 1 of 2
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These data suggest that S845 phosphorylation increases
the plasma membrane levels of GluR1 by reducing the
rate of endocytosis.
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Elevation of surface GluR1 and reduction of GluR1 endocy-tosis by cGMPFigure 2
Elevation of surface GluR1 and reduction of GluR1 
endocytosis by cGMP. A. cGMP, elevates surface GluR1. 
B. cGMP decreases endocytosis of GluR1.Page 2 of 2
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